Hormonal
Low free testosterone levels predict increased mortality from cardiovascular disease (CVD) in older men, whereas low testosterone is not associated with mortality from other causes.
For older men, low free testosterone is a specific warning sign for heart-related death risk, not necessarily for all causes of death. While this suggests checking hormone levels might help assess cardiovascular risk, it does not support using testosterone therapy as a general anti-aging or longevity treatment. Focus on cardiovascular health markers rather than assuming low T alone dictates lifespan.
Low free testosterone predicts mortality from CVD but is not associated with death from other causes.
Why this rating
Large population-based cohort (n=3637), long follow-up (mean 5.1 years), and use of competing-risks models reduce bias, though it remains observational.
Source
Low Free Testosterone Predicts Mortality from Cardiovascular Disease But Not Other Causes: The Health in Men Study
Zoë Hyde et al. · The Journal of Clinical Endocrinology & Metabolism · 2011
DOI 10.1210/jc.2011-1617
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →